Wyze Biotech
A biotechnological company
About Wyze Biotech
Wyze Biotech, officially known as Guangdong Ruishun Biotechnology Co., Ltd., is a biopharmaceutical firm established in 2012, focusing on the clinical development of immune cell therapies. The company was founded in Hangzhou and later relocated its headquarters to Zhongshan, Guangdong, in 2021. Founder and Chairman, Dr. Liming Yang, holds a postdoctoral degree from the University of Toronto's School of Medicine and has three decades of experience in immunology. He is a key inventor of the DNT cell technology that forms the core of the company's research.
The company's primary business involves developing 'off-the-shelf' universal immune cell drugs to treat malignant tumors and autoimmune diseases. Wyze Biotech operates on a business model that encompasses the entire lifecycle of its therapeutic products, from research and development to production and eventual commercialization. Its market consists of patients with critical illnesses, particularly those with conditions like relapsed or refractory acute myeloid leukemia. The company has secured significant funding, raising a total of \$29.9M, with a Series A round in October 2021 bringing in 137 million RMB (approximately \$21.4M), led by Fuho Capital and with participation from investors like Baidu Ventures.
Wyze Biotech's main offering centers on its proprietary Double Negative T (DNT) cell technology platform. DNT cells are a naturally occurring subset of T cells that can be extracted from healthy donors, standardized, and stored for ready use, which helps manage production costs. The company's leading product candidate, RC1012, is an injectable DNT cell therapy. In November 2020, it received investigational new drug (IND) approval from China's National Medical Products Administration to begin clinical trials for treating acute myeloid leukemia. This marked the first non-genetically edited allogeneic T-cell drug to enter registration clinical trials in China. The company is also leveraging its DNT platform by integrating it with CAR-T, gene-editing, and iPSC technologies to develop a pipeline of next-generation cell therapies targeting various blood and solid tumors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- China
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 25.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2022 | $9M | $108M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Dec 2021 | $22M | $86M | Undisclosed | — |
Growth signals
Latest recorded traffic for Wyze Biotech is 5K monthly website visits, up 400% over the last three months. Wyze Biotech's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Wyze Biotech in its local ecosystem
The Wyze Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wyze Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wyze Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









